Prostate Cancer is now the most common cancer type in men, and in their lifetime, one in 8 men will be diagnosed with the disease. However, not all cases of prostate cancer are aggressive - our research is to understand which patients can be kept under surveillance, saving them from unnecessary invasive surgery and its life-changing effects.

The Bob Champion Cancer Trust research laboratories at The Institute of Cancer Research and the University of East Anglia are working with the Pan Prostate Cancer Group to analyse test results using Artificial Intelligence. These tests reveal two distinct forms of prostate cancer, called Evotypes, with one being discovered as an aggressive prostate cancer. These results could revolutionise how the disease is managed, giving clinicians valuable data on which patients will require treating with an aggressive form of prostate cancer whilst sparing those that may not require treatment. The team are also working to develop a genetic test that will provide a more precise prognosis allowing for personalised treatment decisions.